Home/Tag: KIT

Mechanisms of Disease Persistence in Gastrointestinal Stromal Tumors

By Tamas Ordog, LRG Research Team, Martin Zörnig and Yujiro Hayashi Dr. Tamas Ordog Gastrointestinal stromal tumors (GIST) represent a substantial proportion of human bone and soft tissue sarcomas.1 GIST are thought [...]

By |2019-10-31T12:01:09-04:00October 16th, 2015|News, Research|

LRG patient registry: powerful tool for patients, physicians and researchers

The time it takes between the appearance of first symptoms of a rare disease and when the correct diagnosis is given, is often years if not decades instead of days or weeks like it is [...]

By |2019-09-20T12:41:08-04:00October 24th, 2014|News, Patient Registry, Research, Tissue Bank|

Ponatinib Found to Have Therapeutic Potential for Drug-Resistant KIT mutations in GIST

A recent article in the Clinical Cancer Research Journal discussed a new drug, Ponatinib, that shows therapeutic potential for drug-resistant KIT mutations in GIST.

By |2019-09-20T13:34:35-04:00October 3rd, 2014|News, Patient Support, Research|

Sosipatros Boikos takes helm at NIH Clinic

Dr. Sosipatros Boikos, a graduate of University of Crete in Greece, very early and while he was a first year medical student, developed an interest in cancer genetics. After graduating from medical school, he came to the National Institutes of Health as a Visiting Research Fellow to work on the genetics of Wildtype gastrointestinal stromal tumors—those GIST tumors without a KIT or PDGFRA mutation—under the supervision of Dr. Constantine Stratakis, the researcher who identified Carney-Stratakis Syndrome.

By |2019-09-20T12:16:19-04:00August 9th, 2013|Clinical Trials, Events, News, Pediatric GIST|

LRG & colleagues make their mark on 17th annual CTOS meeting in Prague

Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.

By |2019-09-20T13:18:16-04:00February 1st, 2013|Events, News|

Understanding How GISTs Develop Enables Discovery of New Therapies

By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team   Researchers talk plainly about microGISTs, how this cancer develops and what all [...]

By |2019-09-20T13:22:48-04:00January 23rd, 2013|Clinical Trials, Diagnosis, GIST Education, Mutations, News, Research|

The challenge of imatinib resistance in GIST

By Jonathan Fletcher, M.D. & Sebastian Buaer, M.D. Within the past decade, GISTs have emerged from being poorly defined, treatment-resistant tumors to a well recognized, well understood, and treatable tumor entity. Rapid advances in the understanding [...]

By |2019-12-30T09:53:24-05:00December 1st, 2008|News|

MSK team finds rare new mutation

Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York have found a rare mutation in some GIST tumors. In a series of 61 patients with wild-type GIST, they found that three of them (5%) had mutations in a gene called BRAF. This same mutation, a “V600E” mutation in exon 15 of the BRAF gene, occurs frequently in melanoma. They also found the same mutation in one of 28 GIST patients that were resistant to Gleevec.

By |2019-12-30T10:54:23-05:00September 11th, 2008|Research|
Go to Top